Please Note: This course has varying hours depending on the type of credit you need. See Below.
Commission on Dietetic Registration (CDR) - Provider #21328, Activity #153194 approved for 2 CPEUs.
CPEU Course Description
The emergence of nanotechnology applied to medicine has revolutionized the treatment of human cancer. This CPEU course summarizes the importance of the epigenetic alterations identified in human cancer, which have led to the appearance of biomarkers of epigenetic drugs in precision medicine. The transport and release systems of the epigenetic drugs that have been developed to date are also described.
Brooke H. Dekofsky, MPH, RD, CLE, CDE was involved in the creation of this course.
Article Author: Annalisa Roberti, M.D., et al.
Exam writer: Tiev LaGuire, M.S.
CPEU Course Objectives
1. Compare and contrast six different types of RNA molecules.
2. Conclude which histone amino acid the acetylation of is almost always correlated with chromatin accessibility and transcriptional activation.
3. Explain how lipid nanocarriers can protect a drug from degradation.
4. Identify what have been proposed as safe and biocompatible carriers especially for agents that show limited tissue penetration or are rapidly inactivated.
5. List four tumor-targeting ligands.
6. Name the fatty acid conjugated to the azacytidine molecule to develop the CP-4200 prodrug.
CPE Level: II
Learning Codes: 2050, 3070, 5150, 5420
Performance Indicators (RDN): 6.2.5, 8.1.2 , 8.1.5 , 8.3.5
Performance Indicators (NTDR): 6.2.5, 8.1.2 , 8.3.5, 8.3.7
Did you know you can now get UNLIMITED CPEUs for only $75/year?
Click Here to learn more.
Course Date: 2019-07-30
Our courseware includes the text content found on our websites as well as video, audio, and exam questions that make up our courses. You can link to and access our courseware free of charge for personal use. You may not modify or redistribute our courseware under any circumstances.
Although we allow free access for personal use, you may not use our courseware for any commercial purposes without an agreement in place. This includes (but is not limited to) using our courseware for internal training, redistributing our courseware for sale, and copying all or parts of any of our courseware.
If you're interested in licensing our content for commercial purposes or have any other questions, please contact firstname.lastname@example.org.
We will disclose, in advance, any proprietary interest in any product, instrument, device, service, or material to be discussed during the learning event, as well as the source of any third-party compensation related to the presentation. This policy applies to both our organization and contractors. If such proprietary/financial interests exist, we will publish a disclaimer in marketing or instructional materials for a course.
In order to view this course, you will need to be able to view a PDF document for the course material. If your device doesn't have the capability to view a PDF, you can click here to download Adobe Acrobat for free.
The board approval status information is provided based on our current understanding of the licensing agencies. Please note that it is the responsibility of each licensee to verify acceptance of our courses with their licensing agency.